Use of LAK cells with interleukin-2 (IL2) in patients with metastatic cancers has shown some response with many side effects (i.e., extravascular fluid extravasation, anemia, fever, rash, diarrhea). To define the mechanism of target cell lysis and explain some of these side effects, we investigated the target structures of LAK cells. Cell lines were used as targets for LAK lysis in a 4 hr. chromium51 release assay. Cell surface antigens on targets (i.e,, Ia2,Fc79,TR) were determined by immunaflourescence with their respective monoclonal antibodies. Results show that TR, which is present on many transformed cells, and more significantly, on some normal cells, is a target of LAK cytotoxicity, Tumor cell lines (K562,Daudi) used as targets for LAK lysis (both '60% lysed) express TR (>50%+). In contrast, blasts of 3 children with ALL did not express TR (<lo%+) and were poorly lysed by LAK cells (<25%) It has been reported recently that the risk of contracting HB infection from chronic red cell transfusion is low if blood is obtained from volunteer donors and screened for HB surface antigen (SAg); immunization with HB vaccine is thus not recopmended (J. Ped 1986;108:252). We have reviewed our experience with HB in 24 patients, most with sickle cell disease and cerebrovascular accident. Transfusion duration ranged from 1-15 years (median 7) and donor exposure in 1985 14-49 units (mean 26)lptn. Patients are transfused with frozen deglycerolized packed cells from volunteer donors screened for HBSAg. Three patients have shown evidence of HB infection. Two sero-converted after 2% and 3 years of transfusion and were asymptomatic. A third patient began regular transfusions in 11/84 at 11 mos. of age due to recurrent acute splenic sequestration. HBSAg was first detected in 2/85 and has persisted through 5/86 despite seroconversion by 4/85. Serum ALT reached a maximum of 1675 U/1 in 4/85; the child was and remains clinically well. HB core AB and delta antigen were negative and HBeAg positive in 7/85. While HB infection was clinically mild, it has occurred in 3/24 patients; 1 child has become a chronic carrier of HB with significant social, if not medical, consequences, Additional concerns regarding possible interactions between HB, hemochromatosis, and non-A-non-B hepatitis have led us to immunize all sero-negative patients receiving chronic red cell transfusions.
metastatic cancers has shown some response with many side effects (i.e., extravascular fluid extravasation, anemia, fever, rash, diarrhea). To define the mechanism of target cell lysis and explain some of these side effects, we investigated the target structures of LAK cells. Cell lines were used as targets for LAK lysis in a 4 hr. chromium51 release assay. Cell surface antigens on targets (i.e,, Ia2,Fc79,TR) were determined by immunaflourescence with their respective monoclonal antibodies. Results show that TR, which is present on many transformed cells, and more significantly, on some normal cells, is a target of LAK cytotoxicity, Tumor cell lines (K562,Daudi) used as targets for LAK lysis (both '60% lysed) express TR (>50%+). In contrast, blasts of 3 children with ALL did not express TR (<lo%+) and were poorly lysed by LAK cells (<25%), while blasts of an adult ALL patient It has been reported recently that the risk of contracting HB infection from chronic red cell transfusion is low if blood is obtained from volunteer donors and screened for HB surface antigen (SAg); immunization with HB vaccine is thus not recopmended (J. Ped 1986; 108:252) . We have reviewed our experience with HB in 24 patients, most with sickle cell disease and cerebrovascular accident. Transfusion duration ranged from 1-15 years (median 7) and donor exposure in 1985 14-49 units (mean 26)lptn. Patients are transfused with frozen deglycerolized packed cells from volunteer donors screened for HBSAg. Three patients have shown evidence of HB infection. Two sero-converted after 2% and 3 years of transfusion and were asymptomatic. A third patient began regular transfusions in 11/84 at 11 mos. of age due to recurrent acute splenic sequestration. HBSAg was first detected in 2/85 and has persisted through 5/86 despite seroconversion by 4/85. Serum ALT reached a maximum of 1675 U/1 in 4/85; the child was and remains clinically well. HB core AB and delta antigen were negative and HBeAg positive in 7/85. While HB infection was clinically mild, it has occurred in 3/24 patients; 1 child has become a chronic carrier of HB with significant social, if not medical, consequences, Additional concerns regarding possible interactions between HB, hemochromatosis, and non-A-non-B hepatitis have led us to immunize all sero-negative patients receiving chronic red cell transfusions. 778, 1986 ) that a decreased incidence of early, usually thrombotic, CVA may play a role in improving survival prompted us to ascertain the a-globin gene status of our SS population with CVA. Restriction endonuclease analysis using BamHI and BglII was performed on blood of 16 patients ranging in age from 2-10 years(mean 7yrs) at the time of CVA. Fourtccn patients had the normal alpha-4 genotype and 2(12.5%) had a single gene "rightward" deletion. One a-thal SS patient developed a left hemiparesis and CAT scan evidence of bilateral infarction at age 27 nos., 24 mos. after completing a year of regular transfusion for recurrent acute splenic sequestration; hemoglobin at the time of CVA was 7.2gm/dl. In spite of chronic transfusion therapy, she suffered a transient ischemic attack with right hemiparesis 6 years later related to acute anemia(hgb 6.6gm/dl), viral illness, and an enlarged spleen. The other patient with a single gene deletion and SS has done well on regular transfusion since presenting with right hemiparesis at age 7 yrs; hgb was 7.9 gm/dl and MCV 82 fl prior to CVA. The presence of a-thal does not preclude the possibility of CVA in young SS patients; large series with appropriate controls will be required to ascertain the degree Yo which the risk of CVA maybereduced.
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We determined levels of N -r s oncogene amp1 if icat iori and RNA expression in two infants with stage IV-S neuroblastoma, a rare subtype with limited metastatic potential artd generally favorable outcome. Patient 1, age 5 mo, had a primary adrenal tumor with bone marrow metastasis and unfavorable histolo<ji< featdres. Patient 2, age 9 mo, had a primary adrenal tumor wltli skin and marrow metastases of favorable h~stology. Souttlern blots of chromosomal DNA from tumors of both ~patlents showed no amplification of N -m . RNA from the primary 'umor of patient 1 exhibited approximately 16-fold enhanced expression of N -a compared to a neuroblastoma cell 11ne known to express a single copy of N -u (defined a5 baseline). RNA from the primary tumor and involved lymph node of patient 2 revealed baseline levels of N -u expression; a subcutaneous nodule exhibited 5-fold enhanced levels of expressian, whlle normal adrenal tissue had no detectable levels of expression. A cell llne was established from tumor cells of patient 2; these cells appeared to differentlate more readily than cell lines from stage IV tumors. Patient 1 manifested disease progression 1 month after diagnosis, while patient ? remains disease free. Molecular and cellular characterization thus pred~cted the biological behavior of the tumors in each case.
